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Abstract
A recently emerged approach for tissue engineering is to biofabricate tissues using cellular spheroids as
building blocks. Humanpluripotent stem cells (hPSCs), including human embryonic stem cells
(hESCs) and induced pluripotent stem cells (iPSCs), can be cultured to generate large numbers of cells
and can presumably be differentiated into all the cell types of the human body in vitro, thus are an ideal
cell source for biofabrication.Wepreviously developed a hydrogel-based cell culture system that can
economically produce large numbers of hPSC spheroids.With hPSCs and this culture system, there
are two potentialmethods to biofabricate a desired tissue. InMethod 1, hPSC spheroids are first
utilized to biofabricate an hPSC tissue that is subsequently differentiated into the desired tissue. In
Method 2, hPSC spheroids are first converted into tissue spheroids in the hydrogel-based culture
system and the tissue spheroids are then utilized to biofabricate the desired tissue. In this paper, we
systematicallymeasured the fusion rates of hPSC spheroids without andwith differentiation toward
cortical andmidbrain dopaminergic neurons and found spheroids’ fusion rates dropped sharply as
differentiation progressed.We foundMethod 1was appropriate for biofabricating neural tissues.
1. Introduction
Tissue engineering combines engineering principles
and life science to repair, regenerate or restore the
formats and functions of injured or dysfunctional
tissues or organs [1–4]. In scaffold-based tissue
engineering, a porous material is fabricated using
biocompatible and/or biodegradable polymers [5, 6].
Living cells are then seeded onto the scaffold and the
construct is cultured in a bioreactor in vitro to achieve
the desired cell density, mechanical properties and/or
functions before implantation. This classic approach
has achieved many successes, but also has limitations
[1, 5–11]. For instance, it is very challenging to
generate vasculature; to achieve the organ-level cell
density; and to precisely place specific cell types at the
desired position in the construct. The mechanical
properties of the scaffold and the products resulting
from the scaffold degradation sometimes change the
cell viability, proliferation, phenotype and physiology.
In addition, due to the slow scaffold degradation and
tissue morphogenesis, this approach is labor, time and
reagent consuming.
A recently emerged approach for tissue engineering
is to biofabricate tissues using cellular spheroids as build-
ing blocks [5, 6, 12]. Large numbers of human cells are
first obtained andprocessed intomulticellular spheroids,
with a diameter of hundreds of micrometers, through
methods including re-aggregation, microfluidics, hang-
ing drop,micro-molds, spinner culture and rotatingwall
vessels [5, 6, 12, 13]. With the re-aggregation method,
cells are centrifuged in a tube to form a pellet that is then
cut into small fragments that are subsequently cultured
to form spheroids.With the hanging dropmethod, small
volumes of cell suspensions are placed on a lid that is
subsequently inverted to form hanging drops. Cells in
each hanging drop aggregate to formone spheroid.With
the microfluidic and micro-mold methods, cells are
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placed in micro-wells to form one spheroid per well.
With the spinner culture and rotating wall vessel meth-
ods, large numbers of cells are cultured in suspension in
the spinner flasks or rotating wall vessels to simulta-
neously generate many spheroids. Next, the cellular
spheroids are dispensed into a desired geometry, using a
bio-printer or amold.Upon contact, neighboring spher-
oids fuse to form a cohesive tissue due to the cell-cell and
cell-matrix interactions. Lastly, the fused tissue is cul-
tured in abioreactor tomature before implantation.
This scaffold-free approach has been investigated
for biofabricating many types of human tissue [13].
However, there are some challenges to be resolved
[13]. The first is to obtain large numbers of human
cells for the biofabrication. It is known that isolating
large numbers of primary cells from a patient is chal-
lenging and only very limited human cell types can be
cultured in vitro. In addition, when cultured, primary
human cells quickly change phenotype and lose pro-
liferation capability. Assuming we have sufficient cells,
the second challenge is to quickly and reproducibly
bioprocess them into uniform spheroids. The afore-
mentioned re-aggregation, microfluidics, hanging
drop, and micro-molds lack the capability to produce
spheroids in large scale [13]. And with spinner culture
and rotating wall vessel methods, the size and char-
acteristics of the produced spheroids are not uniform
[14, 15]. In addition, the numbers of spheroids that
can be produced per volume of culture is low, result-
ing in high production costs [14, 15]. The third chal-
lenge is that, after being placed in position, spheroids
fuse slowly, which will negatively impact the sub-
sequent tissuematuration [13].
We explored whether these challenges could be
resolved using human pluripotent stem cells (hPSCs)
as the starting cell source. hPSCs, including human
embryonic stem cells (hESCs) [16] and induced plur-
ipotent stem cells (iPSCs) [17], can be cultured in vitro
over a long term to generate large numbers of cells,
and they can presumably be differentiated into all the
cell types of the human body [18]. For instance, hPSCs
have been successfully differentiated into cortical neu-
rons [19, 20], gamma-aminobutyric acid interneurons
[21–23], midbrain dopaminergic neurons [24, 25],
endothelial cells [26–28], mesenchymal stem cells
[29, 30], cardiomyocytes [31–33], hepatocytes [34–
36], beta cells [37, 38] and other human cell types in
the past decade. Additionally, patient-specific iPSCs
and their derivatives (i.e. cells differentiated from
iPSCs) induce minimal or no immune rejection in the
patient. These characteristics make hPSCs an ideal cell
source for tissue biofabrication.
Conventionally, hPSCs are cultured in two-
dimensional (2D) dishes or flasks. However, these 2D
culture systems are considered unsuitable for eco-
nomic large-scale cellular biomanufacturing due to
their low yield, scalability, and reproducibility [39, 40].
In addition, cells produced in 2D cell culture systems
need further bioprocessing to form spheroids. To
overcome this challenge, we previously developed
a simple, efficient, scalable, and current Good
Manufacturing Practice (cGMP) compliant three-
dimensional (3D) culture system for expanding and
differentiating hPSCs to generate hPSC spheroids and
tissue spheroids (e.g. neuron spheroids) [14, 15, 40].
The system utilizes a thermoreversible PNIPAAm-
PEG hydrogel as scaffolds for culturing hPSCs. Single
hPSCs are suspended in liquid PNIPAAm-PEG poly-
mer solution at ∼4 °C. Upon heating to 37 °C, the
polymer solution gels to form an elastic matrix, result-
ing in single hPSCs encapsulated in the hydrogel
matrix that grow into uniform hPSC spheroids within
the hydrogel. With further culturing in a differentia-
tion medium, these hPSC spheroids can be differ-
entiated into tissue spheroids. This culture system
enables us to economically produce large numbers of
hPSC and tissue spheroids for tissue biofabrication.
With hPSCs and this culture system, there are two
potential methods to biofabricate a desired tissue. In
Method 1, hPSC spheroids are utilized to biofabricate
an hPSC tissue that is subsequently cultured in a med-
ium capable of differentiating the hPSC tissue into the
desired tissue. The key for Method 1 to succeed
includes: (1) hPSC spheroids can quickly fuse to form
an hPSC tissue, and (2) hPSCs in the hPSC tissue can
be differentiated into the desired tissue cells. In
Method 2, hPSC spheroids are first converted into tis-
sue spheroids in the PNIPAAm-PEG hydrogel culture
system and the tissue spheroids are utilized to biofab-
ricate the desired tissue. Since we have shown hPSC
spheroids could be efficiently differentiated into tissue
spheroids in the PNIPAAm-PEGhydrogel [15, 41, 42],
the key forMethod 2 to succeed is that tissue spheroids
can quickly fuse to form a cohesive tissue. In this
paper, we will use the biofabrication of 3D neural tis-
sues as examples to explore these questions and to find
out which method is more appropriate for tissue bio-
fabrication using hPSCs as cell source.
2.Materials andmethods
2.1. Culturing hPSCs in 2D
iPSCs (iPSCs reprogrammed from human mesenchy-
mal stem cells) were obtained from George Q. Daley
laboratory (Children’s Hospital Boston, Boston) [43].
H9 hESCs were purchased from WiCell Research
Institute. hPSCs (iPSCs andH9s)weremaintained in a
6-well plate coated with Matrigel (BD Biosciences)
in Essential 8TM medium (E8, Invitrogen) [18]. Cells
were passaged every 4 days with 0.5 mM EDTA
(Invitrogen) and the medium was changed daily. Cells
were routinely checked for the expression of pluripo-
tency markers, Oct4 and Nanog, their capability to
form teratomas in immunodeficient mice, their kar-
yotypes and bacterial contaminations.
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2.2. Biomanufacturing hPSC spheroids in
PNIPAAm-PEGhydrogels
To transfer the culture from 2D to 3DPNIPAAm-PEG
hydrogels, hPSCs maintained in Matrigel-coated
6-well plate were treated with Accutase (Life Technol-
ogies) at 37 °C for 5 min and dissociated into single
cells [14, 15]. Dissociated cells were mixed with 10%
PNIPAAm-PEG (Cosmo Bio, USA) solution dissolved
in E8 medium on ice and cast on tissue culture plate,
then incubated at 37 °C for 10 min to form hydrogels
before adding warm E8 medium containing 10 μM
ROCK inhibitor (Y-27632, Selleckchem). Medium
was changed daily and cells were routinely passaged
every 5 days. To passage cells, medium was removed,
and 2 ml ice-cold PBS was added to dissolve the
hydrogel for 5 min. Cell spheroids were collected by
spinning at 100 g for 3 min. Cells were incubated in
Accutase (Invitrogen) at 37 °C for 10 min and disso-
ciated into single cells, and dissociated into single
cells for re-encapsulation, as mentioned above. The
NucleoCounter NC-200 (Chemometec) was used to
count cell number.
2.3. hPSC spheroids differentiation and fusion
experiment
hPSCs (∼3000 cells) in 200 μl E8mediumwas placed in
one V-shape low attachment well of a 96-well plate for
48 h to form one hPSC spheroid. For cortical neuron
differentiation, the hPSC spheroid was cultured in a
cortical neuron induction medium containing 50%
DMEM/F12+50%Neurobasal medium, 1%N2 (Life
Technologies), 2% B27 (Life Technologies), SB431542
(10 μM, Selleckchem) and LDN193189 (100 nM, Sell-
eckchem) for 11 days to differentiate hPSCs into cortical
progenitor cells. Medium was changed daily. The
progenitor cells were matured in a neural differen-
tiation medium containing Neurobasal® Media (Life
Technologies), BDNF (20 ngml−1, PeproTech), GDNF
(10 ngml−1, PeproTech), L-ascorbic acid (200 μM,
Sigma), Dibutyryl-cAMP (0.5 mM, Santa Cruz Biotech-
nology) and 2.5 μMDAPT (Selleckchem) for another 20
days. For ventralmidbrain dopaminergic neuron differ-
entiation, the hPSC spheroid was cultured in a ventral
midbrain neuron induction medium containing 50%
DMEM/F12+50% Neurobasal medium, 1% N2, 2%
B27, SB431542 (10 μM), LDN193189 (100 nM),
CHIR99021 (0.7 μM, Selleckchem), purmorphamine
(2 μM, Selleckchem) and SHH (200 ngml−1, R&D
Systems) for 11 days to differentiate hPSCs into DA
progenitor cells. Medium was changed daily. The
progenitor cells werematured in a neural differentiation
mediumcontainingNeurobasal®Media (Life Technolo-
gies), BDNF (20 ngml−1), GDNF (10 ngml−1),
L-ascorbic acid (200 μM), Dibutyryl-cAMP (0.5 mM)
and 2.5 μMDAPT for another 20 days. For the spheroid
fusion experiments, on varied days along the differentia-
tion, two spheroids were placed in one V-shape well of
the 96-well plate. The fusion process was then imaged
withmicroscopy.
2.4. Neural tissue biofabrication
Spheroids containing about 5–10 million hPSCs were
harvested from the PNIPAAm-PEG hydrogel on day
5, suspended in E8 medium and placed in a 6.5 mm
Polyester Membrane Transwell Insert (8 μm pore,
Corning). Cells were then cultured in the cell culture
incubator. For some samples, 5 h later, the medium
was removed and a thin layer of ECM (5 μl) (Matrigel,
BDBiosciences)was overlaid on top of the fused tissue.
Medium was added back to culture the cells. To
biofabricate the cortical neural tissue, the fused hPSC
tissue was cultured in the cortical neuron induction
medium for 11 days and matured in the neural
differentiation medium for another 20 days. To
biofabricate the ventral midbrain dopaminergic
neural tissue, the fused hPSC tissue was cultured in the
ventral midbrain neuron induction medium for 11
days and the neural differentiation medium for
another 20 days.
2.5. Staining and imaging
To assess the pluripotency of hPSCs cultured in
hydrogels, hPSC spheroids were harvested and dis-
sociated into single cells with Accutase and stained in
suspension. Cells were fixed with 4% paraformalde-
hyde (PFA) at room temperature for 15 min, permea-
bilized with 0.25% Triton X-100 for 10 min, and
blocked with 5% goat serum for 1 h before incubating
with primary antibodies at 4 °C overnight. After
extensive washing, secondary antibodies and 10 μM
4′,6-Diamidino-2-Phenylindole (DAPI) in 2% BSA
were added and incubated at room temperature for
4 h. Cells were washed 3 times with PBS before
imaging with a fluorescence microscope. The percent-
age of Oct4+ or Nanog+ nuclei was quantified with
Image J. Around 10 000 cells were analyzed.
To stain, the 3D tissues were fixed with 4% PFA at
room temperature for 2 h, then incubated with
PBS+0.25% Triton X-100+5% goat serum+
primary antibodies at 4 °C for 3 days. After extensive
washing (3×8 h), secondary antibodies and 10 μM
DAPI in 2% BSA was added and incubated at 4 °C for
1 day. Cells were washed with PBS for 3 times (8 h each)
before imaging with confocal microscope. Antibodies
used: Oct4 (1:200, Santa Cruz Biotech); Nanog (1:200,
Santa Cruz Biotech); PAX6 (1:300, Covance); Otx2, Tuj1
(1:5000, Sigma); Tbr1, FOXA2 (1:200, Santa Cruz Bio-
tech); Lmx1a (1:500, Millipore) and TH (1:500, Pel-
Freez). The images were analyzed with Image J for quan-
tification.Around5000 cellswere analyzed.
3. Results
We first confirmed that large numbers of uniform
hPSC spheroids could be economically produced in
3
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the thermoreversible PNIPAAm-PEG hydrogel [15].
We used both H9 hESCs and iPSCs to test the
generality of the culture system. Single hPSCs grew
into uniform spheroids on day 5 (figures 1(a)–(c)).
hPSCs expanded around 5-, 10- and 20-fold on day 3,
4, and 5 of the culture, yielding around 5, 10, and
20×106 cells per ml of hydrogel, respectively
(figures 1(d) and (e)). hPSC spheroids could be
harvested by liquefying the hydrogel through cooling
their temperature, i.e. adding ice-cold PBS for 5 min
hPSCs could be cultured for multiple passages within
the hydrogel with around 20-fold expansion every 5
Figure 1.Biomanufacturing hPSC (H9 and iPSC) spheroids in thermoreversible PNIPAAm-PEGhydrogels. Single hPSCswere
encapsulated in the PNIPAAm-PEGhydrogel and cultured in the Essential 8 (E8)medium. Single hPSCs (a) grew into uniform
spheroids (b). On day 5, spheroids were harvested (c). Around 5-, 10- and 20-fold expansionwas achieved, yielding∼5, 10 and 20
million cells perml of hydrogel on day 3, 4 and 5, respectively ((d), and (e)). Consistent 20-fold expansion per 5 dayswas seen from
passage 1 to 5 during the long-termhPSC culture within the hydrogel (f). After long-term culturing, above 95% cells were positive for
the pluripotencymarkers, Oct4 andNanog (g). (h)These hPSCs could be differentiated into theNestin+ ectodermal,α-SMA+
mesodermal andHNF-3β+ endodermal cells in the in vitro embryoid body assay. (i)When transplanted tomice, they formed
teratomas containing all the three germ layer tissues, such as the ectodermal neural rosette, themesodermal cartilage and endodermal
gut-like structure (arrows). Scale bars: 100 μm.
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days (figure 1(f)). After long-term culture, >95% of
the cells remained pluripotency as shown by the
expression of pluripotency markers, Nanog and Oct4
(figure 1(g)). Their pluripotency was further con-
firmed with the embryoid body assay in vitro and
teratoma assay in vivo. hPSCs could be differentiated
into Nestin+ ectodermal cells, α-SMA+mesodermal
cells and HNF-3β+ endodermal cells in the embryoid
body assay (figure 1(h)). When transplanted to NOD-
SCID mice, hPSCs formed teratomas containing all
the three germ layer tissues, such as the ectodermal
neural rosette, the mesodermal cartilage tissues and
the endodermal gut-like structures (figure 1(i)). In
summary, large numbers of hPSC spheroids could be
readily made in the thermoreversible PNIPAAm-PEG
hydrogels.
Based on the literature [44], we then developed
protocols for differentiating hPSC spheroids into cor-
tical neural tissue spheroids and ventral midbrain
dopaminergic neural tissue spheroids. For cortical
neural tissue differentiation, a cortical neuron induc-
tion medium containing small molecules LDN193189
and SB431542, which inhibit the dual SMAD signaling
[44], was applied for 11 days to induce hPSCs into cor-
tical progenitors. The spheroids were further cultured
in a neural differentiatingmedium for an additional 20
days to mature the progenitor cells into neurons
(figure 2(a)). On day 7, immunostaining showed
∼90% cells in the spheroid were positive for the neural
stem cell makers, PAX6 and Nestin (figures 2(b) and
(d)). On day 30, ∼80% cells in the spheroid were
Tuj1+neurons (figures 2(c) and (d)). For dopami-
nergic neural tissue differentiation, a neural induction
medium containing small molecules LDN193189,
SB431542, purmorphamine and CHIR99021, as well
as protein SHH was applied to the hPSC spheroid for
11 days [24]. LDN193189 and SB431542 can induce
hPSCs toward neural lineage, while SHH and purmor-
phamine can pattern cells to the ventral fate and
CHIR99021 can pattern cells to the midbrain fate.
Together, thesemolecules pattern hPSCs to the ventral
midbrain dopaminergic neuron progenitor cells [24].
The spheroid was further cultured in the aforemen-
tioned neural differentiating medium for an addi-
tional 20 days to mature the progenitor cells into
neurons (figure 2(e)). On day 11, ∼90% cells in the
spheroid were positive for the ventral midbrain pro-
genitor makers, FOXA2 and Lmx1a (figures 2(f) and
(h)). On day 30, ∼80% cells in the spheroid were Tuj1
+ and ∼50% tyrosine hydroxylase positive (TH+)
ventral midbrain dopaminergic neurons (figures 2(g)
and (i)). No significant cell death was observed during
the differentiation.
Quick and efficient spheroid fusion is crucial for
the subsequent tissue maturation and thus is required
for rapid tissue biofabrication, especially through bio-
printing. We then quantitatively studied the fusion
rate of undifferentiated and differentiated hPSC
spheroids (figures 3 and 4). One hPSC spheroid was
placed in a V-shape low attachment well of a 96-well
plate and differentiated to a cortical neural tissue
spheroid using aforementioned protocol (figure 2(a)).
At different days along the differentiation, two spher-
oids were placed in one V-shape well to allow them to
contact quickly. Their fusion process was then recor-
ded with microscopy (figure 3(a)). We used the (πr2)/
(πR2), wherein r and R are the radius of the interface of
the two spheroids and radius of the spheroid, respec-
tively, to quantitatively measure the percentage of the
spheroid fusion completed (figure 3(b)). And t1/2 is
referred to the time when 50% of the fusion is com-
pleted or (πr2)/(πR2)=0.5 (figure 3(c)). We found
that undifferentiated hPSC spheroids completed the
fusion in 5 h. As the differentiation progressed, the
fusion rates of spheroids decreased. The fusion
became extremely slow after 14 days of differentiation.
The t1/2 of undifferentiated hPSC spheroids, spher-
oids differentiated for 4, 7, 14 and 28 days is 2.4, 2.6,
8.1, 66.6 and 90.6 h, respectively (figure 3(c)). Similar
trends were found for ventral midbrain dopaminergic
neural tissue spheroids (figure 4). The t1/2 of undiffer-
entiated hPSC spheroids, spheroids differentiated for
3, 6, 13 and 27 days is around 4.0, 6.0, 9.0, 11.0 and
16.0 h, respectively (figure 4(c)). Based on these
results, we concluded that using neural tissue spher-
oids to biofabricate neural tissues would be limited by
the slow fusion rate, and theMethod 1 described in the
introduction would be more appropriate for biofabri-
cating tissues fromhPSCs.
We then studied whether the fused hPSC tissue
could be differentiated and matured into neural tis-
sues. When spheroids were placed in a Transwell
insert, they sedimented to the bottom and tightly
packed within 10 min due to gravity (figures 5(a) and
(b)) without centrifugation. Phase images showed
packed individual spheroids at 10 min after placing
them in the Transwell insert (figure 5(b), left). After
3 h, they fused to form a continuous tissue with rough
surface (figure 5(b), middle). After 5 h, the surface
became very smooth, indicating the completion of
spheroids’ fusion (figure 5(b), right). Live/dead cell
staining showed very few dead cells within the fused
hPSC tissue (figure 5(c)).
We then treated this hPSC tissue with the cortical
neuron induction medium for 11 days and the neural
differentiation medium for additional 20 days as
described in figure 2(a). On day 5, small islands with
diameters around 100 μmwere frequently observed in
the developing tissue (figure 6(a)). On day 11, a thin
tissue that could not be lifted from the underlying
Transwell insert was formed (figure 6(b)). Immunos-
taining showed ∼75% of the cells in this thin tissue
were positive for the cortical progenitormakers, PAX6
and Otx2 (figures 6(c) and (d)). On day 30, more than
80% cells were Tuj1+ neurons and 50% were positive
for the cortical neuron marker, Tbr1 (figures 6(f) and
(g)). However, we were unable to make a thick, 3D
5
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Figure 2.Differentiating hPSC spheroids into neural tissue spheroids. (a)The protocol formaking cortical neural tissue spheroids. (b)
∼90%cells in the day 7 spheroids were positive for neural stem cellmakers PAX6 andNestin (d). (c)∼80%cells in the day 30 spheroids
were Tuj1+neurons (d). (e)The protocol formaking ventralmidbrain dopaminergic neural tissue spheroids. (f)∼90% cells in the day
11 spheroids were positive for ventralmidbrain progenitormakers Lmx1a and FOXA2 (h). (g)∼80%cells in the day 30 spheroids were
Tuj1+ and∼50%TH+dopaminergic neurons (i). Scale bars: 25 μm.
6
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cortical tissue (figure 6(e)); instead, neurons clustered
into aggregates (figure 6(f)).
We also treated the hPSC tissue with the ventral
midbrain dopaminergic neuron induction medium
for 11 days and the neural differentiation medium for
additional 20 days as described in figure 2(e). Similar
results were obtained. On day 5, cell islands were fre-
quently seen in the developing tissue (figure 7(a)). On
day 11, a thin tissue that could not be lifted from the
underlying Transwell insert was formed (figure 7(b)).
Immunostaining showed∼85% of the cells were posi-
tive for the ventral midbrain progenitor makers,
FOXA2 and Lmx1a (figures 7(c) and (d)). On day 30,
more than 90% cells were Tuj1+ neurons and 50%
were positive for the ventral midbrain dopaminergic
neuron marker, TH (figures 7(f) and (g)). Again, we
were unable to make a 3D tissue (figure 7(e)); instead,
neurons clustered into aggregates (figures 7(e) and (f)).
In summary, although hPSCs could be differentiated
into neurons, the fused hPSC tissues could not be con-
verted into 3Dneural tissues.
Literature studies showed that ECM were neces-
sary for mammalian cells to assemble into 3D tissues
[45]. We hypothesized that the loss of 3D structure
during the hPSC tissue differentiation was due to the
shortage of ECM. To test the hypothesis, a thin layer
(∼5 μm) of Matrigel was overlaid on the hPSC tissue
prior to the neural induction. The hPSC tissue was
then differentiated as aforementioned. Low con-
centration of Matrigel proteins (e.g. the commercial
Matrigel product was diluted 100 fold) was supple-
mented to the culture medium during the 30 days. On
day 5, no cell islands were observed (figure 8(a)), and
on day 11, a soft, transparent and 3D tissue with
Figure 3. Spheroid fusion experiment. hPSC spheroids were differentiated toward cortical neural tissue spheroids, as described in
figure 2(a). On day 0, 1, 4, 7, 14 and 28 along the differentiation, two spheroids were placed in contact and the fusion process was
imaged at 0, 1, 3, 5, 7 and 24 h later. (a)Phase images of their fusion. (b) (r/R)2 is used tomeasure their fusion rates. R and r is referred
to the radius of a spheroid and the radius of the interface of the two fused spheroids, respectively. (c) t1/2, the time to complete 50%
fusion or (r/R)2=½, ismeasured. Scale bars: 200 μm.
7
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thickness around 1 mm was formed (figures 8(b) and
(c)). Immunostaining showed ∼75% of the cells
within the tissue were positive for the cortical pro-
genitor cell markers, PAX6 and Otx2 (figures 8(d) and
(e)). NoNanog+ orOct4+ hPSCswere detected in the
tissue (figure 8(f)). Further maturation in the neural
differentiation medium, a 3D (∼1 mm thickness),
elastic and semi-transparent cortical tissue was pro-
duced (figures 8(g) and (h)). ∼85% of the cells within
the day 30 tissue were Tuj1+ neurons and∼50%were
positive for the cortical neuron marker, Tbr1
(figures 8(i) and (j)).
Similar results were obtained when the hPSC tis-
sue was overlaid with Matrigel and differentiated
toward the dopaminergic neural tissue. On day 5, no
cell islands were observed (figure 9(a)). On day 11, a
soft, transparent and 3D tissue with thicknesses
around 1 mm was formed (figures 9(b) and (c)).
Immunostaining showed ∼85% of the cells within the
tissue were positive for the ventral midbrain pro-
genitor makers, FOXA2 and Lmx1a (figures 9(d) and
(e)). NoNanog+ orOct4+ hPSCswere detected in the
tissue (figure 9(f)). Further maturation in the neural
differentiation medium, an elastic, semi-transparent
Figure 4. Spheroid fusion experiment. hPSC spheroids were differentiated toward ventralmidbrain dopaminergic neural tissue
spheroids, as described infigure 2(e). On day 0, 3, 6, 13 and 27 along the differentiation, two spheroids were placed in contact and the
fusion process was imaged at 0, 1, 3, 5, 7 and 24 h later. (a)Phase images of their fusion. (b) (r/R)2 is used tomeasure their fusion rates.
R and r is referred to the radius of a spheroid and the radius of the interface of the two spheroids, respectively. (c) t1/2, the time to
complete 50% fusion or (r/R)2=½, ismeasured. Scale bars: 200 μm.
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and 3D (∼1 mm thickness) ventral midbrain tissue
was produced (figures 9(g) and (h)). More than 90%
cells were Tuj1+ neurons and 52% were positive for
the ventral midbrain dopaminergic neuron marker,
TH (figures 9(i) and (j)). In summary, hPSC tissues
were successfully converted into 3D neural tissues in
the presence of exogenous ECM.
4.Discussion
We biofabricate neural tissues including the cortical
neural tissue and midbrain dopaminergic tissue to
explore the tissue biofabrication methodology using
hPSCs as starting materials in this study. Compared
with neurons cultured in 2D, 3D neural tissues more
closely resemble the in vivo brain tissues and thus are
superior for investigating neurobiology and diseases,
for drug discovery, and for treating neural diseases
[46]. For instance, in the brains of Alzheimer’s disease
patients, large amounts of insoluble amyloid beta (Aβ)
plaques are formed within the extracellular matrix.
iPSCs derived from AD patients can be made and
differentiated into brain neurons to model the disease
in vitro [47]. However, the production of Aβ plaques
in 2D cell culture is difficult due to the limited
extracellular matrix in 2D cultures. A recent study
showed that, in 3D neural tissues made from neural
stem cells overexpressing three AD-causing genes,
large amounts of Aβ plaques were made within their
ECM [48]. Thus, 3D neural tissues made through the
method developed in this study can be very valuable
Figure 5.Biofabricating hPSC tissues. hPSC spheroids were harvested and placed in a Transwell insert to fuse into a cohesive tissue (a).
Spheroids sedimented to the bottomof the insert within 10 min (b, left). Thewhite dots (red arrows)were the pores of the insert. 3 h
later, a continuous 3D tissuewas formed (b,middle). 5 h later, the surface of the tissue became very smooth, indicating the completion
of the fusion process (b, right). Top views of the samples were shown (b). Live/dead cell staining at 24 h showed very few dead cells
within the tissue (c). Scale bars: 100 μm.
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for modeling brain diseases, particularly those with
pathology in ECMs. In a second example, 3D neural
tissues could be used to study glioblastoma, the most
aggressive brain tumor. Glioblastoma cannot be
completely removed through surgery because the
tumor cells can infiltrate several centimeters into the
surrounding brain tissues. The biofabricated 3D
neural tissues can be used to study how tumor cells
invade the brain tissue. In addition to studying the
biology, these 3D neural tissues can be applied for
discovering drugs that can prevent forming or dissolve
Aβ plaques or stop the tumor cell invasion. Biofabri-
cated 3D neural tissues can also be very useful for
treating neural diseases and injuries. Transplanting of
neural stem cells or neurons is being widely investi-
gated for treating neural diseases and injuries. A
current challenge with cell transplantation is the low
survival of the transplanted cells in vivo. In general,
about 5% to 10% of the cells can survive, limiting the
efficacy of cell therapies [49]. Our laboratory research
Figure 6.Biofabricating cortical neural tissues. The hPSC tissuewas treatedwith neural induction and neural differentiationmedium
as described infigure 2(a). Cell islands (outlinedwithwhite dash lines) appeared on day 5 (a) during the differentiation. A thin cell
sheet was formed on day 11 (b). Thewhite dots seen in (b)were the pores of the insert. 75%of the cells were positive for the cortical
neuron progenitormarkers, PAX6 andOtx2 ((c) and (d)). On day 30, cells were differentiated into cortical neurons. 80%of the cells
were Tuj1+neurons and 50%were Tbr1+ cortical neurons ((f) and (g)). No 3Dneural tissues were formed. Cells aggregated into
clusters (red arrows) ((e) and (f)). ((a), (b) and (e))Top views of the tissue. Scale bars: 50 μm.
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as well as other research has shown that transplanting
3D neural tissues, rather than 2D cell cultures, could
significantly improve cell survival and function in vivo
[50]. Thus, biofabricated 3D tissuesmay be better than
cells as cellular products for regenerativemedicine.
As aforementioned, large numbers of hPSC spher-
oids are required for tissue biofabrication. To scale up
the hPSC production, three-dimensional (3D) sus-
pension culture systems, such as spinner flasks and
stirred-tanks have been studied [40, 51]. Three com-
ponents, cells; a medium; and stirring or shaking are
within these systems. Ideally, the seeded single hPSCs
initially associate to form small clusters that subse-
quently expand to generate uniform spheroids. In rea-
lity, these spheroids frequently aggregate during the
culture to form large agglomerates, resulting in two
negative consequences [52]. First, the produced
spheroids varied significantly in their size and
Figure 7.Biofabricating ventralmidbrain dopaminergic neural tissues. The hPSC tissuewas treatedwith neural induction and neural
differentiationmedium as described infigure 2(e). Cell islands (white arrows) appeared on day 5 (a)during the differentiation. A thin
cell sheet was formed on day 11 (b). Thewhite dots seen in (b)were the pores of the insert. Above 85%of the cells were positive for the
ventralmidbrain dopaminergic neuron progenitormarkers, FOXA2 and Lmx1a ((c) and (d)). On day 30, cells were differentiated into
dopaminergic neurons. 90%of the cells were Tuj1+neurons and 50%were TH+ dopaminergic neurons ((f) and (g)). No 3D tissues
were formed. Cells aggregated into clusters (black arrows) ((e) and (f)). ((a), (b) and (e))Top views of the tissue. Scale bars: 50 μm.
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characteristics. Second, it is well known that the trans-
port of nutrients, oxygen and growth factors, and
the metabolic waste from cells located at the center
of agglomerates with diameters >500 μm become
insufficient, leading to slow cell proliferation, apopto-
sis, and uncontrolled differentiation [53]. While stir-
ring or shaking reduces spheroid agglomeration, they
also generate hydrodynamic stress that negatively
Figure 8.Biofabricating cortical neural tissues in the presence of exogenous ECM.The hPSC tissuewas overlaidwith a thin layer of
Matrigel and treatedwith neural induction and neural differentiationmedium as described infigure 2(a). Cell islands were not seen on
day 5 (a) during the differentiation. A 3D, soft and transparent tissuewas formed on day 11 ((b) and (c)). 75%of the cells were positive
for the cortical neuron progenitormarkers, PAX6 andOtx2 ((d) and (e)). NoNanog+ orOct4+hPSCswere found in the tissue (f). A
3D, elastic and semi-transparent cortical tissue was formed on day 30 ((g) and (h)). 85%of the cells were Tuj1+neurons and 55%were
Tbr1+ cortical neurons ((i) and (j)). ((a), (b) and (g))Top views of the tissue. Scale bars: 50 μm.
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affects cell growth [54, 55]. High cell density in the
culture also promotes spheroid agglomeration [14].
Considering all these factors, in current suspension
culture studies, hPSCs are generally seeded at low
density (e.g., ∼3×105 cells/mL) and stirred at 70 to
120 rotations-per-minute (rpm). Under even these
Figure 9.Biofabricating ventralmidbrain dopaminergic tissues in the presence of exogenous ECM.The hPSC tissuewas overlaidwith
a thin layer ofMatrigel and treatedwith neural induction and neural differentiationmedium as described infigure 2(e). Cell islands
were not seen on day 5 (a) during the differentiation. A 3D, soft and transparent tissuewas formed on day 11 ((b) and (c)). Above 85%
of the cells were positive for the ventralmidbrain dopaminergic neuron progenitormarkers, FOXA2 and Lmx1a ((d) and (e)). No
Nanog+ orOct4+ hPSCswere found in the tissue (f). A 3D, elastic and semi-transparent ventralmidbrain tissuewas formed on day
30 ((g) and (h)). 93%of the cells were Tuj1+neurons and 52%were TH+ dopaminergic neurons ((i) and (j)). ((a), (b) and (g))Top
views of the tissue. Scale bars: 50 μm.
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optimized conditions, slow cell growth, significant cell
death, phenotype change, genomic mutations, and
low volumetric yield are common [40]. For instance,
we and others showed iPSCs typically expanded 4-fold
per 4 days to yield around 2.0×106 cells/mL in sus-
pension cultures [14, 15, 40]. It is good to note that
cells occupy <0.2% of the medium or bioreactor
volume with this yield. This low yield results in extre-
mely high biomanufacturing cost. This challenge can
be answered with the PNIPAAm-PEG hydrogel cul-
ture system (figure 1). The hydrogel scaffold not only
provides space for cell growth, but also acts as physical
barriers to prevent the neighboring spheroids from
agglomeration and isolate the hydrodynamic stress.
These lead to high cell viability, proliferation and yield,
as well as uniform spheroid size. For instance, 20-fold
expansion per 5 days to yield 2.0×107 cells has been
achieved.
An essential requirement for rapid tissue biofabri-
cation is that spheroids can quickly fuse to form a
cohesive tissue. Culturing hPSCs in 3D thermo-
reversible PNIPAAm-PEG hydrogels allowed the pro-
duction of spheroids which contained both cells and
their native ECM (figure 1) [56]. Spheroids placed in
contact with one another quickly fused into 3D tissues.
The driven force for tissue fusion is the minimization
of the tissue surface free energy [57, 58]. Through tis-
sue fusion, cells can maximize their interactions with
neighboring cells and ECM. hPSC spheroids harvested
from hydrogel sedimented, packed and fused within
3 h (figures 5(a) and (b)). No cell death was observed
during the fusion (figure 5(c)). Notably, when hPSCs
from 2D cultures or dissociated spheroids (e.g. single
cells) were placed in contact, a minimal of 24 h were
required for cells to fuse into a cohesive tissue and
large percentage of cells went apoptosis (data not
shown), indicting the importance of the native ECM
for the spheroid fusion and highlighting the advantage
of using the PNIPAAm-PEG hydrogels for culturing
hPSCs.
An important finding of this study is that the
fusion rate decreased significantly once hPSC spher-
oids were differentiated (figures 3 and 4). This is parti-
cularly obvious for the cortical neural tissue spheroids
(figure 3). This phenomenon leads us to conclude that
a more appropriate method to biofabricate neural tis-
sues is to fuse hPSC spheroids first, followed by differ-
entiating and maturing the hPSC tissue. Importantly,
our study also showed that the hPSCs in the hPSC tis-
sue could be differentiated into neurons with proto-
cols similar to these used for differentiating hPSCs into
neurons in 2D culture (figure 2). It should be noted
that not all the hPSCs in the biofabricated tissues were
differentiated into the desired neurons in this study.
These biofabricated tissues are appropriate for model-
ing diseases and drug discovery. For in vivo applica-
tion, the differentiation protocols should be optimized
to quantitatively convert hPSCs into the desired neu-
rons in the future.
The finding that extra ECM were needed to form
3D neural tissues during the differentiation of hPSC
tissues can be explained by the inability of neurons to
produce enough ECM (figures 6 to 9). In vivo, the
ECM in the brain are produced by glia cells [59]. In the
biofabricated tissues, there are no or little glia cells to
produce ECM.Matrigel was supplemented as exogen-
ous ECM to facilitate the 3D tissue formation in this
research. Matrigel, a solubilized basement membrane
preparation extracted from the mouse sarcoma, how-
ever, is animal-derived, not defined, and not qualified
for biomanufacturing cells for clinical applications
[60]. Future research to replaceMatrigel is necessary in
order to biomanufacture 3D tissues for clinical appli-
cation. Notably, adding exogenous ECMs did not sig-
nificantly change the differentiation process and
efficiency. The cellular compositions in the day 11 and
day 30 tissues produced without or with exogenous
ECM were very similar (figure 6 versus 7 and figure 8
versus 9).
Biofabricating tissues through first fusing hPSC
spheroids, followed by differentiation and maturation
is simple, however, this also has limitations. First, the
biofabricated tissues lack vasculature. A solution to
this challenge is to use bio-printer to print a sacrificing
hydrogel network in the hPSC tissue [61]. After the
hPSC tissue becomes the mature neural tissue, the
sacrificing hydrogel network is removed and endothe-
lial and smoothmuscle cells are seeded to the channels
to form the vasculature. Both the PNIPAAm-PEG and
alginate hydrogels can be used for this purpose. They
can be removed by cooling the temperature or adding
EDTA for a few minutes. The second challenge is to
biofabricate neural tissues with multiple types of neu-
rons. This challenge can be solved by using the pro-
genitor tissue spheroids as building blocks to
biofabricate the cohesive tissue. For instance, the day
11 cortical progenitor and the day 11 ventral midbrain
progenitor tissue spheroids can be bio-printed into a
cohesive tissue that can be further matured into a
neural tissue with two types of neurons. Our study
showed the progenitor spheroids could fuse, through
their fusion rates were slower than hPSC spheroids
(figures 3 and 4).
5. Conclusion
In summary, this study explored some fundamentals
and methods for biofabricating tissues using hPSCs as
the cell source. We found: (1) the PNIPAAm-PEG
hydrogel culture systemwas excellent for biomanufac-
turing hPSC spheroids; (2) the spheroid fusion experi-
ment was a quick and efficient method to evaluate the
fusion capability of tissue spheroids; (3) the fusion
rates of differentiated spheroids were significantly
lower than hPSC spheroids; (4) hPSCs could be
differentiated into tissue cells in the 3D tissues; and (5)
the method by first fusing hPSC spheroids, followed
14
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with differentiation and maturation was appropriate
for tissue biofabrication.
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